Kenya - English - Pharmacy and Poisons Board

intas pharmaceuticals ltd chinubhai centre off. nehru bridge ashram road - amphotericin - injection - amphotericin 50mg - antimycotics for systemic use: antibiotics

Canada - English - Health Canada

cheplapharm arzneimittel gmbh - amphotericin b - powder for solution - 50mg - amphotericin b 50mg - polyenes

Canada - English - Health Canada

leadiant biosciences, inc - amphotericin b - suspension - 5mg - amphotericin b 5mg - polyenes

Canada - English - Health Canada

astellas pharma canada inc - amphotericin b - powder for solution - 50mg - amphotericin b 50mg - polyenes

Canada - English - Health Canada

three rivers pharmaceuticals llc - amphotericin b - powder for suspension - 100mg - amphotericin b 100mg - polyenes

Canada - English - Health Canada

three rivers pharmaceuticals llc - amphotericin b - powder for suspension - 50mg - amphotericin b 50mg - polyenes

Israel - English - Ministry of Health

gilead sciences israel ltd - amphotericin b - powder for concentrate for infusion - amphotericin b 50 mg/vial - amphotericin b - antifungal antibiotic for the treatment of severe systemic and/or deep mycoses where toxicity precludes the use of conventional systemic amphotericin b in effective dosages. this drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. ambisome is also indicated for the treatment of systemic fungal infections in immunocompromised patients (e.g. patients with aids or cancer). ambisome is also indicated for the primary therapy of visceral leishmaniasis in immunocompetent patients and immunocompromised patients (e.g. hiv positive). empirical treatment of presumed fungal infection in febrile neutropenic patients.

Israel - English - Ministry of Health

gilead sciences israel ltd - amphotericin b - powder for concentrate for infusion - amphotericin b 50 mg/vial - amphotericin b - antifungal antibiotic for the treatment of severe systemic and/or deep mycoses where toxicity precludes the use of conventional systemic amphotericin b in effective dosages. this drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. ambisome is also indicated for the treatment of systemic fungal infections in immunocompromised patients (e.g. patients with aids or cancer). ambisome is also indicated for the primary therapy of visceral leishmaniasis in immunocompetent patients and immunocompromised patients (e.g. hiv positive). empirical treatment of presumed fungal infection in febrile neutropenic patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences ltd - amphotericin b liposomal - powder for dispersion for infusion - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - amphotericin b - powder for solution for infusion - 50mg